AstraZeneca

Kvartal R12

R12 visar de senaste 12 månaderna per kvartalsslut.

Resultatrapport

	2022-Q4 jan-dec MUSD
Nettoomsättning	42 998
Product Sales	42 998
Övriga rörelseintäkter	1 353
Collaboration Revenue	1 353
Kostnad sålda varor	−12 391
Cost of sales	−12 391
Bruttoresultat	31 960
Övriga rörelseintäkter	514
Other operating income and expense	514
Försäljnings- & Adm.kostnader	−18 419
Selling, general and administrative expense	−18 419
Forsknings- & utvecklingskostnader	−9 762
Research and development expense	−9 762
Övriga rörelsekostnader	−536
Distribution expense	−536
Rörelseresultat (EBIT)	3 757
Finansiella poster	−1 256
Finance expense	−1 346
Finance income	95
Share of after tax losses in associates and joint ventures	−5
Resultat före skatt (EBT)	2 501
Skatt	792
Taxation	792
Periodens resultat	3 293
Hänförligt till moderbolagets ägare	3 288
Hänförligt till minoritetsintresse	5

Balansrapport

	2022-Q4 jan-dec MUSD
Kassa & likvida medel	6 166
Cash and cash equivalents	6 166
Omsättningstillgångar (exkl. kassa)	16 427
Assets held for sale	150
Derivative financial instruments	87
Income tax receivable	731
Intangible assets	0
Inventories	4 699
Other investments	239
Trade and other receivables	10 521
Summa omsättningstillgångar	22 593
Materiella anläggningstillgångar	9 449
Property, plant and equipment	8 507
Right-of-use assets	942
Immateriella anläggningstillgångar	59 127
Goodwill	19 820
Intangible assets	39 307
Finansiella anläggningstillgångar	1 216
Derivative financial instruments	74
Investments in associates and joint ventures	76
Other investments	1 066
Övriga anläggningstillgångar	4 098
Deferred tax assets	3 263
Other receivables	835
Summa anläggningstillgångar	73 890
Summa tillgångar	96 483

Kortfristiga skulder	25 571
Derivative financial instruments	93
Income tax payable	896
Interest-bearing loans and borrowings	5 314
Lease liabilities	228
Trade and other payables	19 040
Långfristiga skulder	26 798
Deferred tax liabilities	2 944
Derivative financial instruments	164
Interest-bearing loans and borrowings	22 965
Lease liabilities	725
Avsättningar	1 618
Provisions	1 618
Övriga skulder	5 438
Other payables	4 270
Retirement benefit obligations	1 168
Summa skulder	59 425
Aktiekapital	387
Share capital	387
Övrigt eget kapital	36 671
Non-controlling interests	21
Other reserves	2 069
Retained earnings	−574
Share premium account	35 155
Summa eget kapital	37 058
Summa skulder och eget kapital	96 483

Kassaflödesanalys

	2022-Q4 jan-dec MUSD
Löpande verksamheten	6 051
Depreciation, amortisation and impairment	5 480
Fair value movements on contingent consideration arising from business combinations	82
Finance income and expense	1 251
Gains on disposal of intangible assets	−104
Gains on disposal of investments in associates and joint ventures	0
Interest paid	−849
Non-cash and other movements	−692
Profit/(loss) before tax	2 501
Share of after tax losses of associates and joint ventures	5
Tax paid	−1 623
Förändring av rörelsekapital	3 757
Decrease in inventories	3 941
Increase in trade and other payables and provisions	1 165
Increase in trade and other receivables	−1 349
Kassaflöde från löpande verks.	9 808
Investeringsverksamheten	−2 960
Acquisition of subsidiaries, net of cash acquired	−48
Disposal of intangible assets and assets held for sale	447
Disposal of non-current asset investments	42
Disposal of property, plant and equipment	282
Interest received	60
Movement in short-term investments, fixed deposits and other investing instruments	−114
Payment of contingent consideration from business combinations	−772
Payments to associates and joint ventures	−26
Payments upon vesting of employee share awards attributable to business combinations	−215
Purchase of intangible assets	−1 480
Purchase of non-current asset investments	−45
Purchase of property, plant and equipment	−1 091
Finansieringsverksamheten	−6 823
Dividends paid	−4 364
Hedge contracts relating to dividend payments	−127
Issue of loans and borrowings	0
Movement in short-term borrowings	74
Payment of Acerta Pharma share purchase liability	−920
Proceeds from issue of share capital	29
Repayment of loans and borrowings	−1 271
Repayment of obligations under leases	−244
Periodens kassaflöde	25
Ingående kassa	6 038
Övriga differenser, t.ex. valuta	−80
Exchange rate effects	−80
Utgående kassa	5 983

LOGGA IN

PREMIUM KRÄVS